OPDUALAG FDA approval date
The FDA approved OPDUALAG on 18 Mar 2022.
- FDA approval date
- 18 Mar 2022
- Source
- FDA record
Drug identity has not yet been verified against registry records
Also recorded as NIVOLUMAB; RELATLIMAB-RMBW
Included trials
No linked trials for this drug yet. Browse all trials
PDUFA dates and FDA decisions
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2022-03-18Day | OPDUALAG | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761234", "applicant_as_listed_by_fda": "BRISTOL MYERS SQUIBB", "brand_names": ["OPDUALAG"], "active_ingredients": ["NIVOLUMAB", "RELATLIMAB-RMBW"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20220318", "matched_on": "drug record created from this FDA brand name"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |